2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. IMPDH

IMPDH

Inosine-5’-monophosphate dehydrogenase

IMPDH is a purine biosynthetic enzyme that catalyzes the conversion of inosine 5'-monophosphate (IMP) to xanthosine 5'-monophosphate (XMP). This is the rate-limiting step in the de novo biosynthesis of guanine nucleotides (GMP), and the reaction requires the coenzyme nicotinamide adenine dinucleotide (NAD+). There are mainly two subtypes of IMPDH, IMPDH1 and IMPDH2. IMPDH is a regulator of the intracellular guanine nucleotide pool, and is therefore important for DNA and RNA synthesis, signal transduction, energy transfer, glycoprotein synthesis, as well as other process that are involved in cellular proliferation. In addition, IMPDH can regulate the activation and proliferation of lymphocytes and affect the immune response. The abnormal expression of IMPDH is closely related to cancer and autoimmune diseases[1][2].

IMPDH Related Products (3):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-13986A
    (R)-Merimepodib
    		Control
    (R)-Merimepodib is the isomer of Merimepodib (HY-13986), and can be used as an experimental control. Merimepodib (VX-497) is a noncompetitive and oral inhibitor of inosine monophosphate dehydrogenase (IMPDH) with broad spectrum antiviral activities.
    (R)-Merimepodib
  • HY-110217
    BMS-566419
    		Inhibitor 99.68%
    BMS-566419 is an acridone-based inhibitors of inosine 5'-monophosphate dehydrogenase (IMPDH). Inosine monophosphate dehydrogenase (IMPDH) is a key enzyme in the de novo synthesis of guanosine nucleotides. BMS-566419 has clinical utility for the research of transplant rejection.
    BMS-566419
  • HY-117124
    BMS-337197
    		Inhibitor
    BMS-337197 is a IMPDH inhibitor.
    BMS-337197